Vivos Stock Buy Hold or Sell Recommendation

VVOS -  USA Stock  

USD 3.87  0.01  0.26%

Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding Vivos Therapeutics is 'Strong Sell'. Macroaxis provides Vivos Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding VVOS positions. The advice algorithm takes into account all of Vivos Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.

Vivos Advice 

 
Refresh
The advice is provided from Vivos Therapeutics' buy-and-hold perspective. Also, please take a look at Vivos Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. We conduct extensive research on individual companies such as Vivos and provide practical buy, sell, or hold advice based on selected investing horizon and risk tolerance towards Vivos Therapeutics.

Execute Vivos Therapeutics Buy or Sell Advice

The Vivos recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Vivos Therapeutics. Macroaxis does not own or have any residual interests in Vivos Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Vivos Therapeutics' advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Vivos TherapeuticsBuy Vivos Therapeutics
Strong Sell

Volatility

DangerousDetails

Hype Condition

Low keyDetails

Current Valuation

OvervaluedDetails

Odds of Distress

Below AverageDetails

Economic Sensitivity

Slowly supersedes the marketDetails

Analyst Consensus

Not AvailableDetails

Reporting Quality (M-Score)

UnavailableDetails
For the selected time horizon Vivos Therapeutics has a Mean Deviation of 4.74, Semi Deviation of 4.79, Standard Deviation of 8.25, Variance of 68.04, Downside Variance of 25.09 and Semi Variance of 22.97
We provide advice to complement the current expert consensus on Vivos Therapeutics. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time. To make sure Vivos Therapeutics is not overpriced, please validate all Vivos Therapeutics fundamentals, including its price to sales, cash per share, as well as the relationship between the Cash per Share and short ratio . Given that Vivos Therapeutics has a shares owned by insiders of 21.77 %, we advise you to double-check Vivos Therapeutics market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your current risk tolerance and investing horizon.

Vivos Therapeutics Trading Alerts and Improvement Suggestions

Vivos Therapeutics has very high historical volatility over the last 90 days
The company reported the previous year's revenue of 14.54 M. Net Loss for the year was (20.94 M) with profit before overhead, payroll, taxes, and interest of 10.41 M.
Vivos Therapeutics currently holds about 34.2 M in cash with (11.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.5.
Roughly 22.0% of the company outstanding shares are owned by insiders
Latest headline from www.marketscreener.com: Vivos Therapeutics and Candid Announce Strategic Collaboration to Deliver A Comprehensive Sleep Apnea and Orthodontic Treatment Solution - marketscreener.com

Vivos Therapeutics current analysts advice

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Vivos analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Vivos analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Mean Price11.00
Target Median Price11.00
Target High Price12.00
Recommendation Mean2.00
Number Of Analyst Opinions2
Target Low Price10.00
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.

Vivos Therapeutics Returns Distribution Density

The distribution of Vivos Therapeutics' historical returns is an attempt to chart the future uncertainty of Vivos Therapeutics' future price movements. The chart of the probability distribution of Vivos Therapeutics stock daily returns describes the distribution of returns around its average expected value. We use Vivos Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Vivos Therapeutics returns is essential to provide solid investment advice for Vivos Therapeutics stock.
Mean Return0.18Value At Risk-6.95
Potential Upside10.61Standard Deviation8.25
 Return Density 
      Distribution 
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Vivos Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Vivos Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Vivos Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vivos Therapeutics backward and forwards among themselves. Vivos Therapeutics' institutional investor refers to the entity that pools money to purchase Vivos Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Vanguard Group IncCommon Shares383.9 K1.9 M
Royce Associates LpCommon Shares348 K1.7 M
Penn Capital Management Company LlcCommon Shares223.4 K1.1 M
Bard Associates IncCommon Shares215.5 K1.1 M
Archon Capital Management LlcCommon Shares215 K1.1 M
Avalon Investment AdvisoryCommon Shares189.7 K939 K
Perkins Capital Management IncCommon Shares162.5 K804 K
Note, although Vivos Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Vivos Therapeutics Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Vivos Therapeutics or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Vivos Therapeutics stock's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Vivos stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over DOW
0.15
β
Beta against DOW1.09
σ
Overall volatility
8.37
Ir
Information ratio 0.0188

Vivos Therapeutics Volatility Alert

Vivos Therapeutics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Vivos Therapeutics independently to ensure intended market timing strategies are aligned with expectations about Vivos Therapeutics volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Vivos Therapeutics' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Vivos Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Vivos Therapeutics Fundamentals Vs Peers

Comparing Vivos Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Vivos Therapeutics' direct or indirect competition across all of the common fundamentals between Vivos Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Vivos Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Vivos Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Vivos Therapeutics by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Vivos Therapeutics to competition
FundamentalsVivos TherapeuticsPeer Average
Return On Equity(86.27) %(0.31) %
Return On Asset(28.75) %(0.14) %
Profit Margin(106.61) %(1.27) %
Operating Margin(83.90) %(5.51) %
Current Valuation68.58 M16.62 B
Shares Outstanding22.81 M571.82 M
Shares Owned by Insiders21.77 %10.09 %
Shares Owned by Institutions10.13 %39.21 %
Number of Shares Shorted286.2 K4.71 M
Price to Book2.73 X9.51 X
Price to Sales6.09 X11.42 X
Revenue14.54 M9.43 B
Gross Profit10.41 M27.38 B
EBITDA(11.47 M)3.9 B
Net Income(20.94 M)570.98 M
Cash and Equivalents34.2 M2.7 B
Cash per Share1.50 X5.01 X
Total Debt1.27 M5.32 B
Debt to Equity0.034 %48.70 %
Current Ratio4.23 X2.16 X
Book Value Per Share1.60 X1.93 K
Cash Flow from Operations(11.85 M)971.22 M
Short Ratio0.03 X4.00 X
Earnings Per Share(1.28) X3.12 X
Number of Employees13318.84 K
Market Capitalization88.51 M19.03 B
Z Score41.48.72
   Vivos Therapeutics exotic insider transaction detected [view details]

Vivos Therapeutics Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Vivos . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
Accumulation Distribution22705.79
Daily Balance Of Power(0.038462)
Rate Of Daily Change1.0
Day Median Price3.91
Day Typical Price3.9
Market Facilitation Index0.0
Price Action Indicator(0.045)

About Vivos Therapeutics Buy or Sell Advice

When is the right time to buy or sell Vivos Therapeutics? Buying financial instruments such as Vivos Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the stock market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Although Vivos Therapeutics investors may find it confusing at the beginning, most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.

Use Investing Ideas to Build Portfolios

In addition to having Vivos Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Driverless Cars Thematic Idea Now

Driverless Cars
Driverless Cars Theme
Large technology companies, automotive makers, security firms, and thematic ETFs across multiple industries that are directly or indirectly involved in shaping up the development and marketing of self-driving vehicles. Driverless Cars theme has 34 constituents.
View All  Next Launch Driverless Cars
Also, please take a look at Vivos Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note that the Vivos Therapeutics information on this page should be used as a complementary analysis to other Vivos Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for Vivos Stock analysis

When running Vivos Therapeutics price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
The market value of Vivos Therapeutics is measured differently than its book value, which is the value of Vivos that is recorded on the company's balance sheet. Investors also form their own opinion of Vivos Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vivos Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vivos Therapeutics' market value can be influenced by many factors that don't directly affect Vivos Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vivos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Vivos Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vivos Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.